Presentation Title

Photodynamic Therapy Agents: The potential of Metalloporphyrins in Cancer Research

Faculty Mentor

Dr. Michele McGibony

Faculty Mentor Email

mdavis@georgiasouthern.edu

Presentation Type and Release Option

Research Poster Presentation (File Not Available for Download)

Location

COUR Symposium 2021

Presentation Year

2021

Start Date

4-19-2021 12:00 AM

End Date

April 2021

Abstract

After its discovery back in the 1900s, photosensitizers became a critical study for potential treatments and cures for medical issues, including cancer. It was discovered that porphyrins appeared to target and accumulate in proliferating cells, and to reach the cells, a certain wavelength of light with maximum absorbance associated with the porphyrin was necessary to achieve cell death. Photodynamic therapy involves making use of porphyrins or metalloporphyrins as activators when exposed to such light. When activated, these compounds generate reactive oxygen species (ROS), such as HO⁻ or O²⁻, which can react with nucleic acids found in DNA and RNA. In the aim to find novel photosensitizer compounds, two primary synthesized meso-substituted porphyrins, Cu(II) meso-Tetra(4-sulfonatophenyl) porphine (acid form), abbreviated as C975 and meso-Tetra(4-sulfonatophenyl)porphine dihydrochloride 5,10,15,20-Tetrakis(4-sulfonatophenyl)-21H,23H-porphine dihydrochloride, referred to as TI239, will be tested against the two DNA plasmids, pBR322 and pUC19, to determine the extent of DNA cleavage via agarose gel electrophoresis. Results of these studies will be presented and comparisons made against current photosensitizers.

Academic Unit

Department of Chemistry and Biochemistry

This document is currently not available here.

Share

COinS
 
Apr 19th, 12:00 AM Apr 20th, 12:00 AM

Photodynamic Therapy Agents: The potential of Metalloporphyrins in Cancer Research

COUR Symposium 2021

After its discovery back in the 1900s, photosensitizers became a critical study for potential treatments and cures for medical issues, including cancer. It was discovered that porphyrins appeared to target and accumulate in proliferating cells, and to reach the cells, a certain wavelength of light with maximum absorbance associated with the porphyrin was necessary to achieve cell death. Photodynamic therapy involves making use of porphyrins or metalloporphyrins as activators when exposed to such light. When activated, these compounds generate reactive oxygen species (ROS), such as HO⁻ or O²⁻, which can react with nucleic acids found in DNA and RNA. In the aim to find novel photosensitizer compounds, two primary synthesized meso-substituted porphyrins, Cu(II) meso-Tetra(4-sulfonatophenyl) porphine (acid form), abbreviated as C975 and meso-Tetra(4-sulfonatophenyl)porphine dihydrochloride 5,10,15,20-Tetrakis(4-sulfonatophenyl)-21H,23H-porphine dihydrochloride, referred to as TI239, will be tested against the two DNA plasmids, pBR322 and pUC19, to determine the extent of DNA cleavage via agarose gel electrophoresis. Results of these studies will be presented and comparisons made against current photosensitizers.